ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

被引：0

作者：

Kiladjian, Jean-Jacques ^{[1
]}

Marin, Francisca Ferrer ^{[2
]}

Al-Ali, Haifa Kathrin ^{[3
]}

Alvarez-Larran, Alberto ^{[4
]}

Beggiato, Eloise ^{[5
]}

Bieniaszewska, Maria ^{[6
]}

Breccia, Massimo ^{[7
]}

Buxhofer-Ausch, Veronika ^{[8
]}

Cerna, Olga ^{[9
,10
]}

Crisan, Ana Manuela ^{[11
]}

Danaila, Catalin ^{[12
]}

De Stefano, Valerio ^{[13
]}

Dohner, Konstanze ^{[14
]}

Empson, Victoria ^{[15
]}

Tybor, Joanna Gora ^{[16
]}

Griesshammer, Martin ^{[17
]}

Grosicki, Sebastian ^{[18
]}

Guglielmelli, Paola ^{[19
]}

Gutierrez Sr, Valentin Garcia ^{[20
]}

Heidel, Florian ^{[21
]}

Illes, Arpad ^{[22
]}

James, Chloe ^{[23
]}

Koschmieder, Steffen ^{[24
]}

Maria-Theresa, Krauth ^{[25
]}

Krejcy, Kurt ^{[15
]}

Lazaroiu, Mihaela Cornelia ^{[26
]}

Mayer, Jiri ^{[27
]}

Nagy, Zsolt ^{[28
]}

Palandri, Francesca ^{[29
]}

Pappa, Vasiliki ^{[30
]}

Reiter, Andreas ^{[31
]}

Sacha, Tomasz ^{[32
]}

Schlager, Stefanie ^{[15
]}

Schmidt, Stefan Ulrich ^{[33
]}

Terpos, Evangelos ^{[34
]}

Tomuleasa, Ciprian ^{[35
]}

Torregrosa, Jose Miguel ^{[36
]}

Unger, Martin ^{[15
]}

Woelfler, Albert ^{[37
]}

Xicoy, Blanca ^{[38
]}

Klade, Christoph ^{[15
]}

机构：

[1] Hop St Louis, Ctr Invest Clin, Paris, France

[2] HU Morales Meseguer, Serv Anat Patol, Murcia, Spain

[3] Univ Med Halle, Krukenberg Canc Ctr Halle, Halle, Germany

[4] Hosp Clin Barcelona, ICMHO, Hematol Dept, Barcelona, Spain

[5] AOU Citta Salute & Sci, SC Clin Pharmacol, Turin, Italy

[6] INFN Torino, Turin, Italy

[7] Univ Clin Ctr, Gdansk, Poland

[8] Sapienza Univ Rome, Rome, Italy

[9] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Fac Med 3, Dept Hematol, Prague, Czech Republic

[10] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Dept Hematol, Prague, Czech Republic

[11] Fundeni Clin Inst, Ctr Hematol & Bone Marrow Transplantat, Bucharest, Romania

[12] Reg Inst Oncol, Dept Clin Hematol, Iasi, Romania

[13] Catholic Univ, Dept Urol, Fdn Policlin Univ A Gemelli IRCCS, Med Sch, Rome, Italy

[14] Univ Hosp Ulm, Dept Radiol, Ulm, Germany

[15] AOP Hlth, Vienna, Austria

[16] Med Univ Lodz, Copernicus Mem Hosp Lodz, Dept Biostat & Translat Med, Dept Hematooncol, Lodz, Poland

[17] Univ Bochum, Univ Clin Hematol Oncol Hemostaseol & Palliat Care, Johannes Wesling Med Ctr Minden, Bochum, Germany

[18] Med Univ Silesia, Fac Hlth Sci Bytom, Dept Hematol & Canc Prevent, Katowice, Poland

[19] Univ Studi Firenze, Florence, Italy

[20] Univ Alcala, Hosp Univ Ramon & Cajal, Dept Urol, Inst Ramon & Cajal Invest Sanitaria IRYCIS, Madrid, Spain

[21] Hannover Med Sch, Dept Hematol, Hemostasis Oncol & Stem Cell Transplantat, Hannover, Germany

[22] Univ Debrecen, Clin Ctr, Debrecen, Hungary

[23] Univ Bordeaux, Biol Cardiovasc Dis, Inserm, UMR1034, Pessac, France

[24] Aachen Bonn Cologne Dusseldorf CIO ABCD, Ctr Integrated Oncol, Aachen, Germany

[25] Med Univ Vienna, Clin Div Hematol & Hemostaseol, Dept Internal Medicine1, Vienna, Austria

[26] Policlin Diagnost Rapid, Brasov, Romania

[27] Masaryk Univ, Univ Hosp Brno, Brno, Czech Republic

[28] Semmelwe Egyet, Sportorvostan Tanszek, Budapest, Hungary

[29] Ist Ematol Seragnoli, IRCCS Azienda Ospedaliero Universitaria Bologna, Bologna, Italy

[30] Univ Gen Hosp Attikon, Dept Internal Med & Res Unit 2, Athens, Greece

[31] Univ Med Ctr Mannheim, Dept Hematol & Oncol, Mannheim, Germany

[32] Jagiellonian Univ Hosp Krakow, Krakow, Poland

[33] Med Univ Innsbruck, Dept Internal Med Hematol & Oncol 5, Innsbruck, Austria

[34] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Drosia, Greece

[35] Iuliu Hatieganu Univ Med & Pharm, MedFuture Res Ctr Advance Med, Cluj Napoca, Romania

[36] Univ Poitiers, Chu Poitiers, Poitiers, France

[37] Med Univ Graz, Oncol, Graz, Austria

[38] Univ Autonoma Barcelona, Inst Catala Oncol Badalona, Josep Carreras Leukemia Res Inst, Hosp Univ Germans Trias & Pujol, Barcelona, Spain

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-199028

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6635 / 6637

页数：3

共 50 条

[21] Phase II,Open-Label, Multicenter, Single-Arm Study Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Chinese Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea(HU)
Jin, Jie
Zhang, Lei
Shao, Zonghong
Bai, Jie
Chen, Suning
Duan, Minghui
Zhang, Sujiang
Zhou, Hu
Xu, Na
Du, Xin
Zuo, Xuelan
Wang, Li
Li, Pei
Zhang, Xuhan
Wu, Daoxiang
Li, Yaning
Zhang, Jingjing
Wang, Wei
Shen, Warren
Zagrijtschuk, Oleh
Urbanski, Raymond
Sato, Toshiaki
Qin, Albert
Xiao, Zhijian
BLOOD, 2022, 140 : 6858 - 6859
[22] The Design of a Phase 2 Study to Evaluate the Safety and Efficacy of Ropeginterferon Alfa-2b (P1101) in Chinese Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea (HU)
Jin, Jie
Zhang, Lei
Zhang, Su-Jiang
Chen, Suning
Duan, Minghui
Zhang, Jingjing
Wang, Wei
Shen, Warren
Zagrijtschuk, Oleh
Urbanski, Raymond
Qin, Albert
Xiao, Zhijian
BLOOD, 2021, 138
[23] Evidence for Superior Efficacy and Disease Modification After Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients With Ropeginterferon Alfa-2b Vs HU/BAT
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 10 - 12
[24] A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera
Jin, Jie
Qin, Albert
Zhang, Lei
Shen, Weihong
Wang, Wei
Zhang, Jingjing
Li, Yaning
Wu, Daoxiang
Xiao, Zhijian
FUTURE ONCOLOGY, 2023, 19 (11) : 753 - 761
[25] Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
Mcilroy, Graham
Gaskell, Charlotte
Jackson, Aimee
Yafai, Emily
Tasker, Rachel
Thomas, Catherine
Fox, Sonia
Boucher, Rebecca
Ghebretinsea, Fitsum
Harrison, Claire
Mead, Adam J.
Mcmullin, Mary Frances
BMC CANCER, 2025, 25 (01)
[26] Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT
Gisslinger, Heinz
Klade, Christoph
Georgiev, Pencho
Krochmalczyk, Dorota
Gercheva-Kyuchukova, Liana
Egyed, Miklos
Rossiev, Viktor
Dulicek, Petr
Illes, Arpad
Pylypenko, Halyna
Sivcheva, Lylia
Mayer, Jiri
Yablokova, Vera
Krejcy, Kurt
Grohmann-Izay, Barbara
Hasselbalch, Hans Carl
Kralovics, Robert
Kiladjian, Jean-Jacques
BLOOD, 2018, 132
[27] PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera
Yacoub, Abdulraheem
Abu-Zeinah, Ghaith
Qin, Albert
Tashi, Tsewang
Da'na, Waleed
Shih, Weichung Joe
Zagrijtschuk, Oleh
Tsai, Chan-Yen
Geller, Robert
Komatsu, Norio
Mesa, Ruben
Gill, Harinder
ANNALS OF HEMATOLOGY, 2025, 104 (01) : 335 - 345
[28] Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: Analysis of a prospective randomized phase III trial
Kosmidis, PA
Tsavaris, N
Skarlos, D
Theocharis, D
Samantas, E
Pavlidis, N
Briassoulis, E
Fountzilas, G
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) : 2682 - 2687
[29] Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study (vol 116, pg 215, 2022)
Edahiro, Yoko
Ohishi, Kohshi
Gotoh, Akihiko
Takenaka, Katsuto
Shibayama, Hirohiko
Shimizu, Takayuki
Usuki, Kensuke
Shimoda, Kazuya
Ito, Masafumi
VanWart, Scott A.
Zagrijtschuk, Oleh
Qin, Albert
Kawase, Hiroaki
Miyachi, Narihisa
Sato, Toshiaki
Komatsu, Norio
Kirito, Keita
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (04) : 642 - 643
[30] Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients
Gisslinger, Heinz
Klade, Christoph
Georgiev, Pencho
Skotnicki, Aleksander
Gercheva-Kyuchukova, Liana
Egyed, Miklos
Rossiev, Viktor
Dulicek, Petr
Illes, Arpad
Pylypenko, Halyna
Sivcheva, Liliya
Mayer, Jiri
Grohmann-Izay, Barbara
Hasselbalch, Hans
Kralovics, Robert
Kiladjian, Jean-Jacques
BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →